Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study

Gynecologic Oncology

Volumn 69, Issue 2, 1998, Pages 103-108

  Eisenkop, Scott M ^a   Friedman, Richard L ^a   Wang, He Jing ^b  

^a Womens' Cancer Ctr: Encino Tarzana   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; ILEUS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CANCER; PELVIS EXENTERATION; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; SEROMA; TREATMENT OUTCOME; WOUND INFECTION;

EID: 0032077205     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.4955     Document Type: Article

References (33)

1. Averette H E, Hoskins W, Nguyen H N, Boike G, Flessa H C, Chmiel J S, Zuber K, Karnell L K. National survey of ovarian carcinoma: I. A patient care evaluation study of the American College of Surgeons. Cancer. 71:1993;629-638.
2. Hoskins W J. Primary Cytoreduction. Cancer of the Ovary. 1993;Raven Press, New York. p. 163-173.
3. Eisenkop S M, Nalick R H, Teng N NH. Modified posterior exenteration for ovarian cancer. Obstet Gynecol. 78:1991;879-885.
4. Eisenkop S M, Nalick R H, Wang H, Teng N NH. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol. 51:1993;224-229.
5. Montz F J, Schlaerth J B, Berek J S. Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer. Gynecol Oncol. 35:1989;338-340.
6. Hudson C N. Surgical treatment of ovarian cancer. Gynecol Oncol. 1:1973;370-378.
7. Morrow C P, Curtin J P. Surgery for Ovarian Neoplasia. Gynecologic Cancer Surgery. 1996;Churchill Livingstone, New York.
8. Jodrell D I, Egorin M J, Canetta R M, Langenberg P, Goldblood E P, Burroughs J N, Goodlow J L, Tan S, Wiltshaw E. Relationships between carboplatin exposure and response or toxicity in patients with ovarian cancer. J Clin Oncol. 10:1992;520-528.
9. Friedman R L, Eisenkop S M, Wang H. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival. Gynecol Oncol. 67:1997;88-94.
10. Vogl S E, Pagano M, Kaplan B H, Greenwald E, Arseneau J, Bennett B. Cis-platin based combination chemotherapy for advanced ovarian cancer. Cancer. 51:1983;2024-2030.
11. Pohl R, Dallenbach-Hellweg G, Plugge T, Czernobilsky B. Prognostic parameters in patients with advanced ovarian malignant tumors. Eur J Gynaec Oncol. 3:1984;160-169.
12. Redman J R, Petroni G R, Saigo P E, Geller N L, Hakes T B. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol. 4:1986;515-523.
13. Neijt J P, ten Bokkel Huinink W W, van der Burg M EL, van Oosterom A T, Willemse P HB, Heintz A PM, van Lent M, Trimbos J B, Bouma J, Vermorkena J B, van Houwelingern J C. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian cancer. J Clin Oncol. 5:1987;1157-1168.
14. Hainsworth J D, Jones H W, Burnett L S, Johnson D H, Greco F A. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP). Am J Clin Oncol. 13:1990;410-415.
15. Seifer D B, Kennedy A W, Webster K D, Medendorp S V, Isakson D G. Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinoma. Cleve Clin J Med. 55:1988;555-560.
16. Sutton G P, Stehman F B, Einhorn L H, Roth L M, Blessing J A, Ehrlich C E. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol. 7:1989;223-229.
17. Baker T R, Piver M S, Hempling R E. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian cancer. Cancer. 74:1994;656-663.
18. Del campo J M, Felip E, Rubio D, Vidal R, Bermejo B, Colomer R. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol. 53:1994;27-32.
19. Makar A P, Baekelandt M, Tropé C G, Kristensen G B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 56:1995;175-180.
20. Gershenson D M, Morris M, Burke T W, Levenback C, Kavanagh J J, Fromm G L, Silva E G, Warner B, Wharton J T. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. Gynecol Oncol. 58:1995;349-355.
21. Delgado G, Oram D H, Petrilli E S. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol. 18:1984;293-298.
22. Alberts D S, Liu P Y, Hannigan E V, O'Tolle R, Williams S D, Young J A, Franklin E W, Clarke-Pearson D L, Malviya V K, DuBeshter B, Adelson M D, Hoskins W J. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335:1996;1950-1955.
23. Hacker N F, Berek J S, Lagasse L D, Nieberg R K, Elashoff R M. Primary cytoreductive surgery for ovarian cancer. Obstet Gynecol. 61:1983;413-420.
24. Eisenkop S M, Spirtos N M, Montag T W, Nalick R H, Wang H. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 47:1992;203-209.
25. Potter M E, Partridge E E, Hatch K D, Soong S, Austin J M, Shingelton H M. Primary surgical therapy for ovarian cancer: how much and when. Gynecol Oncol. 40:1992;195-200.
26. Guidozzi F, Ball J H. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 53:1994;326-330.
27. Hoskins W J, Bundy B N, Thigpen J T, Omura G A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 47:1992;167-171.
28. Goodman H M, Harlow B L, Sheets E E, Muto M G, Brooks S, Steller M. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol. 46:1992;367-371.
29. Liu P C, Benjamin I, Morgan M A, King S A, Mikuta J J, Rubin S C. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol. 64:1997;4-8.
30. Curtin J P, Malik R, Venkatraman E S, Barakat R R, Hoskins W J. Stage IV ovarian cancer: Impact of surgical debulking. Gynecol Oncol. 64:1997;9-12.
31. Munkarah A R, Hallum A V, Morris M, Burke T W, Levenback C, Atkinson E N. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 64:1997;13-17.
32. Mcquire W P, Hoskins W J, Brady M F, Kuvera P R, Partridge E E, Look K Y. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med. 334:1996;1-6.
33. Hoskins P J, Swenerton P A, Pike J A, Mcmurtrie E M, Lee N. "MECCA:" a developmental, dose-intense, non-cross-resistent paltinum-based chemotherapy for advanced ovarian cancer. Gynecol Oncol. 63:1996;345-351.